Get the Stockscreener App
2.86
1.78%
0.05
After Hours:
2.91
0.05
+1.75%
Mannkind Corp stock is traded at $2.86, with a volume of 3.00M.
It is up +1.78% in the last 24 hours and up +14.40% over the past month.
MannKind Corp is a biopharmaceutical company focused on the development and commercialization of patient-centric therapies that address serious unmet medical needs for those living with cardiometabolic and orphan lung diseases. The Company is currently commercializing three products: Afrezza (insulin human) Inhalation Powder, an ultra rapid-acting inhaled insulin indicated to improve glycemic control in adults with diabetes; Furoscix (furosemide injection), to treat fluid buildup in patients with chronic heart failure or chronic kidney disease; and the V-Go wearable insulin delivery device, which provides continuous subcutaneous infusion of insulin in adults that require insulin.
See More
Previous Close:
$2.81
Open:
$2.84
24h Volume:
3.00M
Relative Volume:
0.55
Market Cap:
$883.16M
Revenue:
$348.97M
Net Income/Loss:
$5.86M
P/E Ratio:
170.24
EPS:
0.0168
Net Cash Flow:
$13.69M
1W Performance:
+2.51%
1M Performance:
+14.40%
6M Performance:
-52.81%
1Y Performance:
-42.34%
1-Day Range:
$2.83
$2.89
1-Week Range:
$2.68
$2.89
52-Week Range:
$2.23
$6.51
Mannkind Corp Stock (MNKD) Company Profile
Name
Mannkind Corp
Sector
Industry
Phone
818-661-5000
Address
1 CASPER STREET, DANBURY, CA
Compare MNKD vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
MNKD
Mannkind Corp
|
2.86 | 867.72M | 348.97M | 5.86M | 13.69M | 0.0168 |
VRTX
Vertex Pharmaceuticals Inc
|
424.36 | 109.34B | 12.32B | 4.34B | 3.19B | 16.86 |
REGN
Regeneron Pharmaceuticals Inc
|
702.27 | 74.35B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
794.70 | 50.44B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
301.11 | 39.78B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
297.49 | 33.02B | 5.36B | 287.73M | 924.18M | 2.5229 |
Mannkind Corp Stock (MNKD) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Feb-27-26 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Nov-24-25 | Initiated | Truist | Buy |
| Nov-13-25 | Initiated | Leerink Partners | Outperform |
| Oct-20-25 | Initiated | Wells Fargo | Overweight |
| Oct-10-25 | Initiated | Leerink Partners | Outperform |
| Jul-16-25 | Resumed | H.C. Wainwright | Buy |
| Apr-10-25 | Initiated | Mizuho | Outperform |
| Feb-10-25 | Initiated | Wedbush | Outperform |
| Dec-20-24 | Initiated | Wells Fargo | Overweight |
| Dec-19-24 | Upgrade | RBC Capital Mkts | Sector Perform → Outperform |
| Sep-09-24 | Resumed | Leerink Partners | Outperform |
| Jun-13-24 | Initiated | Rodman & Renshaw | Buy |
| Oct-10-23 | Initiated | Wedbush | Outperform |
| May-14-21 | Initiated | RBC Capital Mkts | Sector Perform |
| Dec-24-19 | Initiated | Oppenheimer | Outperform |
| Oct-25-19 | Initiated | Cantor Fitzgerald | Overweight |
| May-14-19 | Initiated | BTIG Research | Buy |
| Mar-04-19 | Initiated | SVB Leerink | Outperform |
| Feb-22-19 | Initiated | SVB Leerink | Outperform |
| Feb-28-18 | Downgrade | Maxim Group | Hold → Sell |
| Nov-01-17 | Downgrade | Maxim Group | Buy → Hold |
| Oct-10-17 | Initiated | H.C. Wainwright | Buy |
| Oct-06-17 | Reiterated | Maxim Group | Buy |
| Aug-11-17 | Initiated | Maxim Group | Buy |
| May-10-16 | Reiterated | Piper Jaffray | Underweight |
| May-10-16 | Reiterated | RBC Capital Mkts | Underperform |
| Jan-06-16 | Reiterated | Piper Jaffray | Underweight |
| Jan-06-16 | Reiterated | RBC Capital Mkts | Underperform |
| Nov-04-15 | Downgrade | RBC Capital Mkts | Outperform → Underperform |
| Sep-09-15 | Downgrade | Piper Jaffray | Neutral → Underweight |
| Aug-03-15 | Reiterated | RBC Capital Mkts | Outperform |
| May-11-15 | Downgrade | JP Morgan | Neutral → Underweight |
| May-11-15 | Reiterated | MLV & Co | Hold |
| Apr-16-15 | Reiterated | RBC Capital Mkts | Outperform |
View All
Mannkind Corp Stock (MNKD) Latest News
Is MannKind Corporation (MNKD) The Best Fundamentally Strong Penny Stock to Invest In Now? - Insider Monkey
MannKind settles $36.3M convertible notes with cash, shares - Investing.com
5 Best Fundamentally Strong Penny Stocks to Invest In Now - Insider Monkey
MannKind (MNKD) Expected to Announce Quarterly Earnings on Wednesday - MarketBeat
MannKind sets May 6 earnings release, 4:30 p.m. webcast - Stock Titan
MannKind to Report First Quarter 2026 Financial Results on May 6, 2026 - ChartMill
MNKD Maintained by Wells Fargo -- Price Target Raised to $8.00 - GuruFocus
MannKind (NASDAQ:MNKD) Trading Up 5.5% Following Analyst Upgrade - MarketBeat
Wells Fargo & Company Boosts MannKind (NASDAQ:MNKD) Price Target to $8.00 - MarketBeat
HC Wainwright Estimates MannKind's Q1 Earnings (NASDAQ:MNKD) - MarketBeat
MannKind (MNKD) CFO has shares withheld for RSU tax obligations - Stock Titan
FY2027 EPS Estimates for MannKind Reduced by HC Wainwright - MarketBeat
How The MannKind (MNKD) Story Is Shifting With Tyvaso DPI And Soft Mist Uncertainty - Yahoo Finance
Why MannKind Corporation (MNKD) is One of the Best Stocks Under $5 With Huge Upside Potential - Insider Monkey
MannKind Corporation (NASDAQ:MNKD) Receives Average Rating of "Moderate Buy" from Analysts - MarketBeat
5 Stocks Under $5 with Huge Upside Potential - Insider Monkey
MannKind (NASDAQ:MNKD) Upgraded at Zacks Research - MarketBeat
MannKind Corporation (NASDAQ:MNKD) Short Interest Up 29.8% in March - MarketBeat
Truist Securities Touts MannKind Corporation (MNKD) Prospects on Tyvaso Franchise Development - Insider Monkey
5 Best Healthcare Penny Stocks to Buy According to Hedge Funds - Insider Monkey
MNKD Maintains Rating by Mizuho -- Price Target Lowered to $8.00 - GuruFocus
Leerink reiterates Outperform on MannKind stock, sees overreaction - Investing.com
Leerink reiterates Outperform on MannKind stock, sees overreaction By Investing.com - Investing.com UK
Risk Check: Is MannKind Corporation in a bullish channel2026 Snapshot & Weekly High Return Opportunities - baoquankhu1.vn
Non Tuberculous Mycobacterial Infections Market: High-Growth Opportunities for Investors to 2034 – DelveInsight | Insmed, AN2 Therapeutics, Mannkind Corp., Spero Therapeutics, Savara Pharmaceuticals - Barchart.com
MannKind (NASDAQ: MNKD) details 2026 virtual meeting, board elections and pay vote - Stock Titan
[ARS] MANNKIND CORP SEC Filing - Stock Titan
MannKind CEO and CFO to speak at two Miami healthcare events - Stock Titan
Q4 2025 MannKind Corp Earnings Call Transcript - GuruFocus
MNKD Stock Price, Quote & Chart | MANNKIND CORP (NASDAQ:MNKD) - ChartMill
Q2 2025 MannKind Corp Earnings Call Transcript - GuruFocus
Truist reiterates MannKind stock rating on partner trial data By Investing.com - Investing.com India
Truist reiterates MannKind stock rating on partner trial data - Investing.com
MannKind Corporation $MNKD Shares Bought by JPMorgan Chase & Co. - MarketBeat
Is MannKind Corporation (MNKD) One of the Popular Penny Stocks on Robinhood to Buy? - Insider Monkey
Vanguard disaggregates holdings; MannKind (MNKD) shows 0 shares in 13G/A - Stock Titan
MannKind (MNKD) EVP receives new performance RSU and option awards - Stock Titan
MannKind (MNKD) awards performance RSUs and stock options to officer - Stock Titan
Setup Watch: Is now the right time to enter MannKind CorporationTrend Reversal & Smart Allocation Stock Reports - baoquankhu1.vn
How The MannKind (MNKD) Story Is Shifting As Tyvaso Risks Meet Afrezza And Furoscix Potential - Yahoo Finance
Chart Watch: Whats the beta of MannKind Corporation stockMarket Risk Summary & Daily Risk Controlled Trade Plans - baoquankhu1.vn
MannKind Corp. Hits Day Low of $3.29 Amid Price Pressure - Markets Mojo
MannKind Corp stock hits new 52-week low on NASDAQ amid analyst downgrades and earnings miss - AD HOC NEWS
MannKind (NASDAQ:MNKD) Hits New 12-Month LowHere's What Happened - MarketBeat
MannKind stock slips despite FDA clearing pediatric use of heart failure drug — what’s spooking investors? - MSN
A Key "Master" Protein That Declines by Half After Age 40. One Company Found a Way to Restore It. - Benzinga
MannKind: Strategic Uncertainty Follows United Therapeutics' Pivot (Rating Downgrade) - Seeking Alpha
Mannkind Corp Stock (MNKD) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.14%
0.48%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):